Last updated: September 8, 2026
Tralokinumab-ldrm, marketed as Adbry in the United States and Adtralza in Europe, is an interleukin-13 inhibitor developed for moderate-to-severe atopic dermatitis. LEO Pharma owns and commercializes the product globally after acquiring rights from Eli Lilly. The drug has established a commercial position in dermatology but faces strong competition from dupilumab, oral JAK inhibitors, and newer biologics targeting the IL-13 pathway.
LEO does not report a separate full-year revenue line for Adbry and Adtralza in every public disclosure. Available company reporting indicates rapid post-launch growth from a low base, supported by geographic expansion and broader pediatric labeling. The principal commercial constraint is market competition rather than near-term loss of regulatory exclusivity.
What is tralokinumab-ldrm and how does it work?
Tralokinumab-ldrm is a fully human monoclonal antibody that selectively binds interleukin-13, a cytokine involved in the inflammatory response associated with atopic dermatitis. It does not inhibit interleukin-4 signaling, distinguishing it mechanistically from dupilumab, which blocks the shared IL-4 receptor alpha subunit used by both IL-4 and IL-13 pathways.
| Product attribute |
Detail |
| Active ingredient |
Tralokinumab-ldrm |
| U.S. brand |
Adbry |
| European brand |
Adtralza |
| Drug class |
Anti-IL-13 monoclonal antibody |
| Company |
LEO Pharma |
| Initial U.S. approval |
December 27, 2021 |
| Initial indication |
Moderate-to-severe atopic dermatitis in adults |
| U.S. pediatric expansion |
Patients aged 12 years and older |
| Administration |
Subcutaneous injection |
| Initial adult regimen |
600 mg loading dose, followed by 300 mg every two weeks |
| Maintenance option |
Every-four-week dosing may be considered in adults with controlled disease |
| Regulatory category |
Biologic drug, subject to the biosimilar pathway under the Public Health Service Act |
The U.S. label permits use as monotherapy or with topical corticosteroids. The principal adverse events include upper respiratory tract infections, conjunctivitis, injection-site reactions, and eosinophilia. The label also contains warnings concerning conjunctivitis and keratitis, helminth infections, and live vaccines. (U.S. Food and Drug Administration [FDA], 2021)
What is the FDA regulatory status of Adbry?
The FDA approved Adbry in December 2021 for adults with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with prescription topical therapies or when those treatments are not advisable. The FDA later expanded the indication to adolescents aged 12 years and older.
The approval was based primarily on the ECZTRA clinical development program. In pivotal trials, tralokinumab demonstrated higher rates of clear or almost clear skin and improvement in Eczema Area and Severity Index scores than placebo. Maintenance data supported continued benefit with every-two-week administration and, for selected patients, every-four-week dosing.
The European Commission approved Adtralza in June 2021 for adults with moderate-to-severe atopic dermatitis. European authorization later expanded to adolescent patients. National reimbursement decisions have differed by country, which affects the pace of European sales conversion.
Key regulatory milestones
| Date |
Milestone |
| June 2021 |
European Commission authorization for adult atopic dermatitis |
| December 2021 |
FDA approval for adult atopic dermatitis |
| 2022 |
U.S. commercial launch |
| 2023 |
U.S. expansion to adolescents aged 12 years and older |
| 2023-2024 |
Continued European pediatric and label expansion activities |
How large is the tralokinumab market?
The commercial market is the systemic moderate-to-severe atopic dermatitis segment. It includes biologics, oral JAK inhibitors, and, increasingly, other targeted immunomodulators.
Dupilumab remains the category leader. Sanofi and Regeneron have expanded Dupixent across multiple indications, improving physician familiarity, payer access, and treatment persistence. Tralokinumab competes most directly on selective IL-13 inhibition, safety positioning, dosing flexibility, and LEO Pharma’s dermatology focus.
| Competitor |
Company |
Mechanism |
Commercial position |
| Dupixent |
Sanofi/Regeneron |
IL-4 receptor alpha blockade |
Category leader with broad indication base |
| Adbry/Adtralza |
LEO Pharma |
IL-13 blockade |
Established second-line or alternative biologic |
| Ebglyss |
Lilly/Almirall |
IL-13 blockade |
Newer direct competitor |
| Nemluvio |
Galderma |
IL-13 receptor alpha 1 blockade |
New entrant in atopic dermatitis |
| Rinvoq |
AbbVie |
JAK1 inhibitor |
High-efficacy oral systemic option |
| Cibinqo |
Pfizer |
JAK1 inhibitor |
Oral systemic competitor |
| Nemolizumab |
Galderma |
IL-31 receptor alpha blockade |
Relevant to pruritus-focused treatment strategies |
The arrival of Ebglyss and Nemluvio increases pressure on tralokinumab because both products compete within the same cytokine pathway or adjacent disease biology. The commercial differentiation available to tralokinumab is therefore limited. LEO must compete through reimbursement, physician access, patient support, dosing, and long-term safety perception.
What is the financial trajectory for tralokinumab-ldrm?
LEO Pharma reported strong growth in Adtralza sales after launch, although the company does not consistently disclose a detailed geographic revenue split or product-level profitability. Public annual reports have identified Adtralza as one of the company’s growth products within dermatology.
The financial trajectory has four stages:
- Pre-launch investment and clinical development.
- Initial launch in Europe and the United States.
- Revenue expansion through pediatric labeling and broader reimbursement.
- Margin pressure as LEO funds market access and competes against larger companies with wider portfolios.
Revenue development
LEO’s public reporting has shown substantial year-over-year growth in Adtralza revenue from its early commercial base. The product remains smaller than Dupixent and does not approach the revenue scale of the leading atopic dermatitis franchise.
| Financial driver |
Effect on tralokinumab |
| U.S. launch |
Created access to the largest commercial biologics market |
| European reimbursement |
Added volume but with country-specific price controls |
| Adolescent approval |
Expanded the addressable patient population |
| Every-four-week maintenance option |
May reduce treatment burden and support persistence |
| Dupilumab dominance |
Limits share capture and payer leverage |
| New IL-13 competitors |
Raises switching and formulary pressure |
| JAK inhibitor competition |
Provides an oral alternative for some patients |
| LEO’s focused portfolio |
Supports specialist promotion but limits scale benefits |
The product’s financial profile is more likely to resemble a durable specialty franchise than a category-dominating blockbuster. It can generate meaningful revenue for LEO if the company maintains reimbursement and captures patients who are inadequately controlled, intolerant of, or unwilling to use alternative therapies. The commercial ceiling is lower than it would have been without Dupixent’s entrenched position and the arrival of additional IL-13 agents.
How does Adbry compare with Dupixent?
Dupixent has the stronger commercial and franchise position. It benefits from approval in atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, prurigo nodularis, chronic obstructive pulmonary disease in selected populations, and other indications. Its broader label supports payer negotiations, physician familiarity, and patient recruitment across specialties.
Tralokinumab has a narrower current franchise and is concentrated in dermatology.
| Factor |
Adbry |
Dupixent |
| Target |
IL-13 |
IL-4 receptor alpha |
| Atopic dermatitis experience |
Later entrant |
First major biologic in the segment |
| Indication breadth |
Primarily atopic dermatitis |
Multiple inflammatory diseases |
| Commercial scale |
Smaller |
Category leader |
| Dosing flexibility |
Every two weeks, with adult every-four-week option in controlled disease |
Dosing varies by indication and age |
| Competitive vulnerability |
High from IL-13 entrants |
Lower because of broad franchise |
| Payer leverage |
More limited |
Stronger due to established demand |
Adbry can still win share where prescribers prefer selective IL-13 inhibition, where patients experience inadequate response or tolerability problems with other therapies, or where local formularies provide favorable access. The drug lacks a broad enough indication base to offset all of Dupixent’s structural advantages.
What patents protect tralokinumab-ldrm?
Tralokinumab is protected through biologic composition, antibody sequence, formulation, manufacturing, and regulatory exclusivity rights. The relevant protection is jurisdiction-specific and does not depend on an Orange Book listing.
Because Adbry is a biologic, the principal U.S. reference-product protections are:
- FDA reference-product exclusivity;
- U.S. patents listed or otherwise asserted in patent litigation;
- Patent-term adjustments and extensions;
- Manufacturing and cell-line know-how;
- Clinical and regulatory data used in the biologics license application.
Adbry is not an ordinary small-molecule product with a conventional Orange Book patent-and-exclusivity profile. The FDA’s Purple Book is the relevant biologic reference for biosimilar and interchangeable-product information. A definitive generic-style launch date cannot be inferred from the drug’s approval date alone.
Does tralokinumab have Orange Book protection?
No conventional Orange Book framework governs Adbry as it would govern a small-molecule drug. The product is regulated under a biologics license application. Patent disputes involving a biosimilar would generally proceed under the Biologics Price Competition and Innovation Act patent-exchange and litigation framework rather than a standard Hatch-Waxman Paragraph IV certification.
Are there Paragraph IV challenges to Adbry?
A conventional Paragraph IV challenge is not the expected pathway for tralokinumab because Adbry is a biologic. A competing product would need to pursue a biosimilar application under section 351(k) of the Public Health Service Act rather than an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act.
Publicly visible commercial risk is therefore tied to:
- Development of a tralokinumab biosimilar;
- Patent litigation under the BPCIA;
- FDA approval of a biosimilar or interchangeable product;
- Regulatory exclusivity and patent expiry;
- Manufacturing capacity and analytical comparability.
No major publicly established biosimilar launch has displaced Adbry in the United States. The practical near-term threat remains branded competition, not commodity-style generic substitution.
What is the biosimilar risk for tralokinumab?
Biosimilar risk is currently lower than branded competitive risk but will increase as the market matures. Monoclonal antibodies require complex cell-culture manufacturing, extensive analytical characterization, and clinical comparability work. These requirements create higher entry barriers than those for conventional generics.
The main barriers are:
- Proprietary cell lines and manufacturing processes;
- Product-specific analytical methods;
- Comparability of glycosylation and higher-order structure;
- Clinical immunogenicity and pharmacokinetic requirements;
- Patent disputes;
- Payer willingness to substitute;
- Physician and patient acceptance.
A future tralokinumab biosimilar could pressure net pricing, particularly if it receives an interchangeable designation or is preferred by large pharmacy benefit managers. The impact would likely develop gradually because biologic prescribing and substitution differ from small-molecule generic markets.
What licensing deals affect tralokinumab?
The commercial history of tralokinumab includes collaboration between LEO Pharma and Eli Lilly. LEO obtained commercial rights and assumed responsibility for development and commercialization under the parties’ arrangements. The transaction enabled LEO to build a major dermatology product without discovering and developing the antibody entirely in-house.
The deal reduced LEO’s internal discovery risk but created dependence on a single principal biologic growth asset. That structure makes Adbry’s sales trajectory important to LEO’s portfolio economics, particularly after LEO’s broader strategic shift toward medical dermatology.
What litigation affects tralokinumab?
There is no widely reported litigation event that has materially delayed Adbry’s launch or established a near-term generic entry date. The principal legal questions are prospective:
- Whether future biosimilar sponsors will challenge composition or manufacturing patents;
- Whether LEO will assert patents under the BPCIA;
- Whether formulation or dosing patents can extend practical market protection;
- Whether patent settlements would delay biosimilar entry;
- Whether international patent outcomes will diverge by market.
The absence of a public Paragraph IV dispute does not eliminate future patent risk. It reflects the biologic regulatory pathway and the product’s current commercial maturity.
What generic launch scenarios exist for Adbry?
Three scenarios are commercially relevant.
Scenario 1: Branded competition without biosimilar entry
This is the most immediate scenario. Adbry continues to grow but loses share to Dupixent, Ebglyss, Nemluvio, and oral JAK inhibitors. Net pricing remains under pressure as payers use step edits and preferred-product strategies.
Scenario 2: Delayed biosimilar entry
A biosimilar sponsor files or prepares a 351(k) product but faces patent litigation or manufacturing delays. LEO retains meaningful exclusivity while discounts increase to defend formulary access.
Scenario 3: Successful biosimilar launch
An approved biosimilar enters after regulatory and patent barriers are resolved. Gross price erosion and mandatory or incentivized substitution reduce Adbry revenue. LEO could preserve part of the franchise through contracting, patient services, and formulation or device differentiation, but the product would face a structural decline in net sales.
How strong is the tralokinumab patent estate?
The estate has commercial value because biologic manufacturing and antibody sequence protection can be difficult to replicate. Its strength depends on the claims that remain enforceable in each jurisdiction and on whether later patents cover clinically meaningful dosing, formulations, devices, or manufacturing steps.
Its relative strength is moderate from a commercial perspective:
- Biologic manufacturing creates a meaningful technical barrier.
- No conventional generic substitution pathway applies.
- The product has a differentiated antibody target.
- The market has several branded alternatives.
- A narrow indication base limits the value of extended protection.
- Competing IL-13 antibodies can capture demand without infringing tralokinumab patents.
Key Takeaways
- Tralokinumab-ldrm is an established but smaller biologic in moderate-to-severe atopic dermatitis.
- LEO Pharma’s Adbry and Adtralza sales have grown from a low launch base, but product-level profitability and complete revenue figures are not consistently disclosed.
- Dupixent remains the commercial benchmark because of its broad indications and early market entry.
- Ebglyss and Nemluvio increase direct IL-13 pathway competition.
- Oral JAK inhibitors remain important alternatives for patients and physicians seeking rapid systemic efficacy.
- Adbry is regulated as a biologic, so biosimilar and BPCIA risks are more relevant than conventional Paragraph IV litigation.
- The principal near-term risk is branded market-share erosion, followed later by potential biosimilar price pressure.
- Pediatric expansion and every-four-week maintenance dosing support demand, but they do not remove the product’s limited indication breadth.
- LEO’s financial exposure is concentrated because tralokinumab is one of its key dermatology growth products.
FAQs
What is the annual revenue of Adbry?
LEO Pharma does not consistently publish a fully separated global annual revenue figure for Adbry and Adtralza in all public financial disclosures. Company reporting identifies the product as a major dermatology growth asset, with sales increasing after its 2021 U.S. approval.
Is tralokinumab safer than dupilumab?
The products have different mechanisms and safety profiles. Tralokinumab is selective for IL-13, while dupilumab blocks IL-4 receptor alpha. Comparative real-world safety conclusions depend on patient population, treatment duration, and adverse-event definitions.
Can tralokinumab be used in children?
In the United States, Adbry is approved for certain patients aged 12 years and older with moderate-to-severe atopic dermatitis. European labeling has also expanded into pediatric populations, subject to local authorization and reimbursement.
Is Adbry interchangeable with Dupixent?
No. Adbry and Dupixent are different biologic products with different molecular targets. Neither is a biosimilar or interchangeable version of the other.
Will a tralokinumab biosimilar reduce Adbry pricing?
A biosimilar could reduce net pricing and market share if it receives FDA approval and achieves favorable payer placement. The timing depends on remaining regulatory exclusivity, patent litigation, manufacturing readiness, and substitution policy.
References
-
European Medicines Agency. (2021). Adtralza: EPAR - product information. European Medicines Agency.
-
LEO Pharma. (2022). Annual report 2022. LEO Pharma A/S.
-
LEO Pharma. (2023). Annual report 2023. LEO Pharma A/S.
-
U.S. Food and Drug Administration. (2021). FDA approves new treatment for moderate-to-severe eczema. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2023). Adbry prescribing information. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
-
U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. U.S. Department of Health and Human Services.
